KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Gross Profit (2021 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Gross Profit for 5 consecutive years, with $21.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit rose 357.78% year-over-year to $21.3 million, compared with a TTM value of $3.7 million through Dec 2025, down 72.59%, and an annual FY2025 reading of $3.7 million, down 72.59% over the prior year.
  • Gross Profit was $21.3 million for Q4 2025 at Recursion Pharmaceuticals, up from -$9.5 million in the prior quarter.
  • Across five years, Gross Profit topped out at $21.3 million in Q4 2025 and bottomed at -$9.5 million in Q3 2025.
  • Average Gross Profit over 5 years is $1.1 million, with a median of $1.3 million recorded in 2023.
  • Peak annual rise in Gross Profit hit 4170.64% in 2024, while the deepest fall reached 915.83% in 2024.
  • Year by year, Gross Profit stood at $2.5 million in 2021, then grew by 11.96% to $2.8 million in 2022, then tumbled by 64.35% to $1.0 million in 2023, then crashed by 915.83% to -$8.2 million in 2024, then soared by 357.78% to $21.3 million in 2025.
  • Business Quant data shows Gross Profit for RXRX at $21.3 million in Q4 2025, -$9.5 million in Q3 2025, and -$938000.0 in Q2 2025.